United Therapeutics Corp. SEC Filings

United Therapeutics Corp. (UTHR) has filed a Form S-8 to register 950,000 additional common shares (par $0.01) for issuance under its Amended & Restated 2015 Stock Incentive Plan. The company relies on General Instruction E, incorporating eight prior S-8 filings that together registered 13,820,000 shares; cumulative authorization for the plan now totals 14,770,000 shares. UTHR is incorporated in Delaware, qualifies as a large accelerated filer, and lists its principal executive offices in Silver Spring, MD.

The filing, signed by Chair & CEO Martine A. Rothblatt on 30 July 2025, contains standard exhibits such as the counsel opinion, auditor consent, and plan document. No financial statements, earnings data, or new corporate events are included; the registration strictly facilitates future equity compensation grants.

United Therapeutics (UTHR) Form 4: EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at an exercise price of $135.42 on 07/24/2025, converting them into common shares. The same day, he disposed of the entire 11,000-share lot through three open-market sales executed under a pre-arranged Rule 10b5-1 plan at weighted-average prices of $303.31, $304.25 and $305.14, generating gross proceeds of roughly $3.3 million and a spread of about $168 per share over the strike price.

Following the transactions Mahon retains 36,781 shares of common stock held directly and continues to hold 99,000 unexercised options (same grant, expiring 03/15/2027). No other classes of securities were affected.

The filing represents routine insider activity disclosed within two business days and does not alter company guidance or fundamentals. Investors often monitor insider sales for sentiment signals; however, the use of a 10b5-1 plan and the retention of a sizable equity stake temper any negative inference.

United Therapeutics (UTHR) filed a Form 4 disclosing that EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at $135.42 and immediately sold the same 11,000 shares on 26 Jun 2025 at weighted-average prices between $283.52 and $288.80, generating gross proceeds of roughly $3.1 million.

The sale, executed under a pre-arranged 10b5-1 plan adopted 24 Dec 2024, reduced Mahon’s direct holdings by about 23 % to 36,781 shares; he still holds 121,000 options. No other executives were involved.

This sizable insider disposition may influence investor sentiment even though it was pre-planned.

United Therapeutics (Nasdaq: UTHR) filed an 8-K covering its June 26 2025 annual meeting. Shareholders re-elected all 13 directors, approved the non-binding say-on-pay vote, and ratified Ernst & Young as auditor. The meeting also approved an amendment and restatement of the 2015 Stock Incentive Plan, adding 950,000 shares, extending the plan to April 24 2035, and increasing the Lead Independent Director retainer by $5,000. No other material financial or operational changes were disclosed.